Latest News and Press Releases

HUDDINGE, Sweden, Sept. 13, 2004 (PRIMEZONE) -- Karo Bio's research operations have been re-engineered in 2004 by strengthening of the efforts in pharmacology and chemistry. With Karo Bio's expressed...

HUDDINGE, Sweden, Aug. 30, 2004 (PRIMEZONE) -- At Karo Bio AB's special general meeting on Monday August 30, 2004 the following was resolved. Approval of decisions on New Share Issue The special...

HUDDINGE, Sweden, Aug. 16, 2004 (PRIMEZONE) -- A special general meeting of the shareholders of Karo Bio Aktiebolag (publ) will be held on Monday August 30, 2004 at 4.00 pm in Strindbergsalen at...

HUDDINGE, Sweden, July 13, 2004 (PRIMEZONE) -- Karo Bio: -- Predevelopment candidate was identified in the Wyeth Pharmaceuticals collaboration yielding milestone revenues for Karo Bio....

HUDDINGE, Sweden, June 18, 2004 (PRIMEZONE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has advanced into predevelopment a lead compound for atherosclerosis from the joint collaboration...

HUDDINGE, Sweden, April 30, 2004 (PRIMEZONE) -- In the fall of 1997 Karo Bio and Bristol-Myers Squibb (BMS) initiated a drug discovery collaboration with the aim to develop novel treatments for...

HUDDINGE, Sweden, April 23, 2004 (PRIMEZONE) -- Karo Bio: -- Substantial progress has been made in the collaboration with Wyeth Pharmaceuticals in the discovery of lead compounds that show...

HUDDINGE, Sweden, April 22, 2004 (PRIMEZONE) -- At Karo Bio AB's Annual General Meeting on Wednesday April 21, 2004, the following was resolved. Dividend No dividend is to be paid for the financial...

HUDDINGE, Sweden, Feb. 06, 2004 (PRIMEZONE) -- Karo Bio: - A preclinical milestone for a second compound was reached and a milestone payment was received in May in the Merck & Co., Inc....

HUDDINGE, Sweden, Nov. 18, 2003 (PRIMEZONE) -- Karo Bio has decided to reduce its presence in North Carolina USA. Technologies, key projects and other research activities will be transferred...